Investee Company News

January 15, 2019 Immunocore names David Berman as Head of R&D January 4, 2019 Immunocore appoints Bahija Jallal as Chief Executive Officer January 4, 2019 Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions January 2, 2019 Novan Announces Management Changes and Provides Business Update December 19, 2018 Melinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million ~ December 19, 2018 John H. Johnson Agrees to Become Permanent Chief Executive Officer of Melinta Therapeutics December 11, 2018 Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit December 10, 2018 Novan Announces Full Top Line Results from Phase 2 Molluscum Contagiosum Clinical Trial and Decision to Move Forward with SB206 12% Once-Daily December 4, 2018 Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting November 30, 2018 Kymab granted leave to appeal to the UK Supreme Court November 29, 2018 Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting November 27, 2018 Melinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam) November 19, 2018 Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech November 14, 2018 Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance in Preliminary Top Line Results November 12, 2018 Novan Announces Corporate Update Conference Call and Webcast November 7, 2018 Melinta Therapeutics Reports Third Quarter 2018 Financial Results November 5, 2018 Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101 October 31, 2018 Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors October 29, 2018 Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP October 25, 2018 Novan Creates Dedicated Women’s Health Business Unit October 22, 2018 Melinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer October 12, 2018 Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan October 5, 2018 Melinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program October 1, 2018 Melinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries October 1, 2018 Novan’s Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November September 25, 2018 Novan Receives FDA Guidance for SB204 and Acne Indication September 21, 2018 Melinta Therapeutics Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam) September 18, 2018 Melinta Therapeutics Names Peter Milligan as Chief Financial Officer September 7, 2018 Mycovia Pharmaceuticals Debuts with Initiation of Phase 3 Clinical Trials for Treatment of Recurrent Vulvovaginal Candidiasis September 6, 2018 Melinta Therapeutics to Host Meetings at the Morgan Stanley 16th Annual Global Healthcare Conference